Clinical trial · Interventional
A Study of the Alternative Administration of Ixabepilone and Vinflunine
A Study of the Alternating Administration of Ixabepilone and Vinflunine Every Three Weeks in Patients With Advanced Cancer
NCT00362830CI-TRIAL-00023919completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the study is to test how vinflunine interacts with ixabepilone in the human body.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| vinflunine + ixabepilone | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 1
- interventionNames
- Drug: vinflunine + ixabepilone
Primary outcomes (1)
- measure
- Determine the maximum tolerated dose and describe any dose limiting toxicities of ixabepilone and vinflunine in an alternating regimen.
- timeFrame
- upon occurrence
Secondary outcomes (1)
- measure
- Determine the overall safety profile, efficacy and rate and extent to which ixabepilone and vinflunine are absorbed or otherwise available to the treatment site in the body.
- timeFrame
- upon occurrence
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * ECOG status of 0-1 Exclusion Criteria: * Inability to tolerate venous access * Brain mets * Severe nerve damage * ANC \<2,000/mm3 * Platelets \<100K * Bilirubin \>= 1.5 times the IULN * ALT/AST \>= 2.5 times the IULN * Creatinine \<50 mL/min * Prior treatment with vinflunine and/or ixabepilone * Strong use of CYPP450 drugs
References
Publications (0)
Data not yet available
No reference posted for this study.